{"id":68460,"date":"2026-04-09T13:06:39","date_gmt":"2026-04-09T07:36:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68460"},"modified":"2026-04-09T13:06:41","modified_gmt":"2026-04-09T07:36:41","slug":"syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/","title":{"rendered":"Syngene International Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Syngene International (NSE: SYNGENE) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 820 \u2014 against a 52-week high of Rs 1,080 and a 1-year return of -20% \u2014 the Q4 FY26 results will be a pivotal event for investors.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 1,050-1,150 Cr, with PAT expectations of Rs 180-210 Cr and margin projections of EBITDA 28-31%. This article covers the Syngene International Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and the most commonly searched investor questions.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Syngene_International_Q4_Results_2026_Date\" title=\"Syngene International Q4 Results 2026 Date\">Syngene International Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Syngene_International_Q4_FY26_Earnings_Estimates\" title=\"Syngene International Q4 FY26 Earnings Estimates\">Syngene International Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#5_Key_Factors_That_Will_Drive_Syngene_International_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Syngene International Q4 FY26 Performance\">5 Key Factors That Will Drive Syngene International Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Revenue_Momentum\" title=\"Revenue Momentum\">Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Margin_Trajectory\" title=\"Margin Trajectory\">Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#PAT_Quality\" title=\"PAT Quality\">PAT Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Management_Guidance_for_FY27\" title=\"Management Guidance for FY27\">Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Dividend_Declaration\" title=\"Dividend Declaration\">Dividend Declaration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#5_Risks_to_Watch_in_Syngene_International_Q4_FY26\" title=\"5 Risks to Watch in Syngene International Q4 FY26\">5 Risks to Watch in Syngene International Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#US_Tariff_and_Macro_Headwinds\" title=\"US Tariff and Macro Headwinds\">US Tariff and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#FY27_Guidance_Below_Consensus\" title=\"FY27 Guidance Below Consensus\">FY27 Guidance Below Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Sector_Regulatory_Risk\" title=\"Sector Regulatory Risk\">Sector Regulatory Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Syngene_International_Share_Price_and_Analyst_Ratings\" title=\"Syngene International Share Price and Analyst Ratings\">Syngene International Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_the_Syngene_International_Q4_results_2026_date\" title=\"What is the Syngene International Q4 results 2026 date?\">What is the Syngene International Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_the_Syngene_International_Q4_FY26_PAT_estimate\" title=\"What is the Syngene International Q4 FY26 PAT estimate?\">What is the Syngene International Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_Syngene_Internationals_share_price_ahead_of_Q4_results\" title=\"What is Syngene International&#8217;s share price ahead of Q4 results?\">What is Syngene International&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Will_Syngene_International_declare_a_dividend_in_Q4_FY26\" title=\"Will Syngene International declare a dividend in Q4 FY26?\">Will Syngene International declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Which_analysts_have_a_Buy_rating_on_Syngene_International\" title=\"Which analysts have a Buy rating on Syngene International?\">Which analysts have a Buy rating on Syngene International?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_were_Syngene_International_Q3_FY26_results\" title=\"What were Syngene International Q3 FY26 results?\">What were Syngene International Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Is_Syngene_International_a_good_investment_ahead_of_Q4_results\" title=\"Is Syngene International a good investment ahead of Q4 results?\">Is Syngene International a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q4-results-2026-date-revenue-pat-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Q4_Results_2026_Date\"><\/span><strong>Syngene International Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Syngene International has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Article<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Syngene International<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Syngene International enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 is the final quarter of FY26 \u2014 it determines full-year performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -20%, this quarter&#8217;s results and FY27 guidance will be critical in determining whether the stock can sustain recovery momentum.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Q4_FY26_Earnings_Estimates\"><\/span><strong>Syngene International Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-1024x536.jpg\" alt=\"Syngene International Q4 FY26 Earnings Estimates\" class=\"wp-image-68473\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 971 Cr<\/td><td>Rs 1,050-1,150 Cr<\/td><td>Volume + pricing<\/td><\/tr><tr><td>PAT<\/td><td>Rs 162 Cr<\/td><td>Rs 180-210 Cr<\/td><td>Operating leverage<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 28.4%<\/td><td>EBITDA 28-31%<\/td><td>Cost control<\/td><\/tr><tr><td>Key Growth Metric<\/td><td>Q3 trend<\/td><td>10-14% YoY revenue growth<\/td><td>Management execution<\/td><\/tr><tr><td>Dividend Estimate<\/td><td>\u2014<\/td><td>Rs 3-5 per share<\/td><td>Board recommendation<\/td><\/tr><\/tbody><\/table><\/figure><p>A positive surprise on any two of the four key parameters \u2014 revenue, margin, guidance, and dividend \u2014 could drive a meaningful post-results re-rating.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Syngene International fundamentals<\/a> on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Syngene_International_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Syngene International Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Momentum\"><\/span><strong>Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts expect Rs 1,050-1,150 Cr in Q4 FY26 revenue (Q3: Rs 971 Cr). Q4 is seasonally important for the Pharma\/CDMO sector, driven by year-end order execution and government capex push. The ability to convert the pipeline into recognised revenue will be the first test.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Trajectory\"><\/span><strong>Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations are EBITDA 28-31%, versus EBITDA 28.4% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Quality\"><\/span><strong>PAT Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Net profit is estimated at Rs 180-210 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean, recurring profit print is most positively received by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Guidance_for_FY27\"><\/span><strong>Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The most consequential output will be FY27 guidance \u2014 revenue bands, margin targets, and capex plans. In the current global macro environment, credible and specific FY27 guidance will be valued more than usual by the market.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividend_Declaration\"><\/span><strong>Dividend Declaration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Syngene International is expected to consider a final dividend of Rs 3-5 per share. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Syngene_International_Q4_FY26\"><\/span><strong>5 Risks to Watch in Syngene International Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Macro_Headwinds\"><\/span><strong>US Tariff and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods has created macro uncertainty across Indian equities. For Syngene International, indirect impacts include FII outflows and potential earnings estimate cuts if global demand slows. A tariff negotiation breakthrough remains the most significant macro upside catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Syngene International&#8217;s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus the Rs 1,050-1,150 Cr estimate and PAT versus Rs 180-210 Cr as the two primary watchpoints on results day.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Below_Consensus\"><\/span><strong>FY27 Guidance Below Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current environment, forward guidance carries more weight than the reported quarter.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling pressure would create headwinds for Syngene International regardless of company-specific fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector_Regulatory_Risk\"><\/span><strong>Sector Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma\/CDMO sector faces evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Syngene International&#8217;s profitability beyond current consensus models.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Share_Price_and_Analyst_Ratings\"><\/span><strong>Syngene International Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-1024x536.jpg\" alt=\"Syngene International Share Price and Analyst Ratings\" class=\"wp-image-68477\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Syngene International is trading at Rs 820 as of early April 2026, against a 52-week high of Rs 1,080 and a 52-week low of Rs 680. Market cap stands at Rs 32,800 Cr. The 1-year return of -20% reflects sector headwinds alongside company-specific factors.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 1,050<\/td><td>Biocon-backed CDMO; MNC clients<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 1,020<\/td><td>Discovery + development + manufacturing<\/td><\/tr><tr><td>JM Financial<\/td><td>Add<\/td><td>Rs 980<\/td><td>Long-term capacity addition FY27-28<\/td><\/tr><tr><td>Bernstein<\/td><td>Outperform<\/td><td>Rs 1,000<\/td><td>India CDMO quality franchise<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Syngene International&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Syngene International Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma\/CDMO sector. Analysts project PAT of Rs 180-210 Cr and revenue of Rs 1,050-1,150 Cr. At a CMP of Rs 820 and analyst targets ranging from Rs 1,000 to Rs 1,050, the stock offers meaningful risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.<\/p><p>For more Q4 FY26 previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Syngene_International_Q4_results_2026_date\"><\/span><strong>What is the Syngene International Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Syngene International Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Syngene_International_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Syngene International Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Syngene International Q4 FY26 PAT at Rs 180-210 Cr, based on revenue of Rs 1,050-1,150 Cr and margin of EBITDA 28-31%. Actual results may differ from consensus.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Syngene_Internationals_share_price_ahead_of_Q4_results\"><\/span><strong>What is Syngene International&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Syngene International is trading at Rs 820. The 52-week high is Rs 1,080 and low is Rs 680. The 1-year return is -20% and market cap is Rs 32,800 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Syngene_International_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Will Syngene International declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Syngene International is expected to consider a final dividend of Rs 3-5 per share at the Q4 FY26 board meeting on May 2026 (Expected).<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Syngene_International\"><\/span><strong>Which analysts have a Buy rating on Syngene International?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (Buy, Rs 1,050), YES Securities (Buy, Rs 1,020), JM Financial (Add, Rs 980), Bernstein (Outperform, Rs 1,000) have positive ratings heading into Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Syngene_International_Q3_FY26_results\"><\/span><strong>What were Syngene International Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Syngene International reported Q3 FY26 revenue of Rs 971 Cr and PAT of Rs 162 Cr, with margin at EBITDA 28.4%. These form the baseline for Q4 FY26 estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Syngene_International_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Syngene International a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite and portfolio context. Syngene International has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor. Use the Univest Screener to assess fundamentals independently.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/mphasis-q4-results-2026\">Mphasis Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/mastek-q4-results-2026\">Mastek Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cyient-q4-results-2026\">Cyient Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/kpit-technologies-q4-results-2026\">KPIT Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zensar-technologies-q4-results-2026\">Zensar Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Syngene International (NSE: SYNGENE) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 820 \u2014 against a 52-week high of<\/p>\n","protected":false},"author":26,"featured_media":68469,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-68460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1775720225:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:69:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Syngene-estimates.jpg\";a:2:{s:2:\"id\";i:68473;s:11:\"source_type\";s:13:\"media-library\";}s:78:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Syngene-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68473;s:11:\"source_type\";s:13:\"media-library\";}s:101:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates.jpg\";a:2:{s:2:\"id\";i:68473;s:11:\"source_type\";s:13:\"media-library\";}s:110:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130432\/Syngene-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68473;s:11:\"source_type\";s:13:\"media-library\";}s:67:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Syngene-analyst.jpg\";a:2:{s:2:\"id\";i:68477;s:11:\"source_type\";s:13:\"media-library\";}s:76:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Syngene-analyst-1024x536.jpg\";a:2:{s:2:\"id\";i:68477;s:11:\"source_type\";s:13:\"media-library\";}s:99:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst.jpg\";a:2:{s:2:\"id\";i:68477;s:11:\"source_type\";s:13:\"media-library\";}s:108:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130508\/Syngene-analyst-1024x536.jpg\";a:2:{s:2:\"id\";i:68477;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_focus_keyword":["Syngene International Q4 Results 2026"],"rank_math_title":["Syngene International Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"],"rank_math_description":["Syngene International Q4 results May 2026 (Expected). PAT estimate Rs 180-210 Cr, margin EBITDA 28-31%. Full Q4 FY26 preview with analyst targets.\n"],"_thumbnail_id":["68469"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7625"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09130309\/Syngene-Q4-results-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68460"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68460\/revisions"}],"predecessor-version":[{"id":68486,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68460\/revisions\/68486"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68469"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}